Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan.
HPB (Oxford). 2023 Dec;25(12):1573-1586. doi: 10.1016/j.hpb.2023.09.002. Epub 2023 Sep 14.
We compared the recurrence-free survival (RFS), overall survival (OS), and safety of laparoscopic liver resection (LLR) between non-alcoholic fatty liver disease (NAFLD) and non-NAFLD hepatocellular carcinoma (HCC) patients.
Patients with HCC (n = 349) were divided into four groups based on the HCC etiology (NAFLD [n = 71], hepatitis B [n = 27], hepatitis C [n = 187], alcohol/autoimmune hepatitis [AIH] [n = 64]). RFS and OS were assessed by multivariate analysis after adjustment for clinicopathological variables. A subgroup analysis was performed based on the presence (n = 248) or absence (n = 101) of cirrhosis.
Compared with the NAFLD group, the hazard ratios (95% confidence intervals) for RFS in the hepatitis B, hepatitis C, and alcohol/AIH groups were 0.49 (0.22-1.09), 0.90 (0.54-1.48), and 1.08 (0.60-1.94), respectively. For OS, the values were 0.28 (0.09-0.84), 0.52 (0.28-0.95), and 0.59 (0.27-1.30), respectively. With cirrhosis, NAFLD was associated with worse OS than hepatitis C (P = 0.010). Without cirrhosis, NAFLD had significantly more complications (P = 0.034), but comparable survival than others.
Patients with NAFLD-HCC have some disadvantages after LLR. In patients with cirrhosis, LLR is safe, but survival is poor. In patients without cirrhosis, the complication risk is high.
我们比较了非酒精性脂肪性肝病(NAFLD)和非 NAFLD 肝细胞癌(HCC)患者的无复发生存(RFS)、总生存(OS)和安全性。
根据 HCC 的病因(NAFLD [n=71]、乙型肝炎 [n=27]、丙型肝炎 [n=187]、酒精/自身免疫性肝炎 [AIH] [n=64]),将 349 例 HCC 患者分为四组。通过多变量分析,在校正临床病理变量后评估 RFS 和 OS。基于是否存在(n=248)或不存在(n=101)肝硬化进行亚组分析。
与 NAFLD 组相比,乙型肝炎、丙型肝炎和酒精/AIH 组的 RFS 危险比(95%置信区间)分别为 0.49(0.22-1.09)、0.90(0.54-1.48)和 1.08(0.60-1.94)。对于 OS,值分别为 0.28(0.09-0.84)、0.52(0.28-0.95)和 0.59(0.27-1.30)。对于存在肝硬化的患者,NAFLD 与 OS 较丙型肝炎差有关(P=0.010)。对于不存在肝硬化的患者,NAFLD 并发症较多(P=0.034),但生存情况与其他组无显著差异。
NAFLD-HCC 患者在接受 LLR 后存在一些劣势。对于肝硬化患者,LR 是安全的,但生存状况较差。对于无肝硬化患者,并发症风险较高。